Clinical Trial Update: Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating JSKN016 in combination therapy for advanced non-small cell lung cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JSKN016

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Advanced Non-small Cell Lung Cancer | Phase 1 | Status: RECRUITING